Trial Profile
A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK1006.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Bekanamycin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 07 Apr 2009 Patient numbers amended from 24 to 16 as reported by ClinicalTrials.gov.
- 07 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2009 Actual initiation date changed from May 2008 to Apr 2008 as reported by ClinicalTrials.gov.